Paul Helft, MD, discusses the rationale for continuing bevacizumab beyond progression in patients with metastatic colorectal cancer.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
Ещё видео!
Paul Helft, MD, discusses the rationale for continuing bevacizumab beyond progression in patients with metastatic colorectal cancer.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]